JP2013528206A5 - - Google Patents

Download PDF

Info

Publication number
JP2013528206A5
JP2013528206A5 JP2013513760A JP2013513760A JP2013528206A5 JP 2013528206 A5 JP2013528206 A5 JP 2013528206A5 JP 2013513760 A JP2013513760 A JP 2013513760A JP 2013513760 A JP2013513760 A JP 2013513760A JP 2013528206 A5 JP2013528206 A5 JP 2013528206A5
Authority
JP
Japan
Prior art keywords
thalidomide
type
crystalline
anhydrous crystalline
anhydrous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013513760A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013528206A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2011/051078 external-priority patent/WO2011154739A1/en
Publication of JP2013528206A publication Critical patent/JP2013528206A/ja
Publication of JP2013528206A5 publication Critical patent/JP2013528206A5/ja
Pending legal-status Critical Current

Links

JP2013513760A 2010-06-09 2011-06-09 結晶形態のサリドマイド及びその調製方法 Pending JP2013528206A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1758MU2010 2010-06-09
IN1758/MUM/2010 2010-06-09
PCT/GB2011/051078 WO2011154739A1 (en) 2010-06-09 2011-06-09 Crystalline forms of thalidomide and processes for their preparation

Publications (2)

Publication Number Publication Date
JP2013528206A JP2013528206A (ja) 2013-07-08
JP2013528206A5 true JP2013528206A5 (enExample) 2014-07-24

Family

ID=44384914

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013513760A Pending JP2013528206A (ja) 2010-06-09 2011-06-09 結晶形態のサリドマイド及びその調製方法

Country Status (8)

Country Link
US (2) US20130143923A1 (enExample)
EP (1) EP2580205A1 (enExample)
JP (1) JP2013528206A (enExample)
CN (1) CN103068812A (enExample)
AU (1) AU2011263493B2 (enExample)
CA (1) CA2801835A1 (enExample)
NZ (1) NZ604011A (enExample)
WO (1) WO2011154739A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102924432A (zh) * 2012-11-09 2013-02-13 常州制药厂有限公司 一种高纯度沙利度胺的制备方法
EP2815749A1 (en) * 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
CN105473558B (zh) * 2013-06-20 2019-04-19 拜耳作物科学股份公司 作为杀螨剂和杀昆虫剂的芳基硫化物衍生物和芳基硫氧化物衍生物
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
MX387318B (es) * 2014-04-14 2025-03-18 Arvinas Operations Inc Moduladores de la proteólisis basados en imida y métodos de uso asociados.
CN104710411B (zh) * 2015-03-13 2017-04-26 安润医药科技(苏州)有限公司 阿伐那非的合成方法
CN110498788B (zh) * 2018-05-16 2021-09-17 欣凯医药化工中间体(上海)有限公司 一种高纯度沙利度胺α晶型的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB768821A (en) 1954-05-17 1957-02-20 Gruenenthal Chemie Novel products of the amino-piperidine-2, 6-dione series
US5463063A (en) 1993-07-02 1995-10-31 Celgene Corporation Ring closure of N-phthaloylglutamines
CN1164586C (zh) 2002-10-28 2004-09-01 中国科学院长春应用化学研究所 沙利度胺及其衍生物的制备方法
US20050182097A1 (en) * 2003-12-30 2005-08-18 Zeldis Jerome B. Methods and compositions using thalidomide for the treatment and management of central nervous system disorders or diseases
ITMI20041113A1 (it) 2004-06-01 2004-09-01 Antibioticos Spa Processo per la sintesi della talidomide
WO2008035378A2 (en) * 2006-09-20 2008-03-27 Matrix Laboratories Ltd An improved process for the preparation of thalidomide
WO2009083724A1 (en) 2007-12-27 2009-07-09 Cipla Limited Processes for the preparation of thalidomide
CN102260241A (zh) * 2010-05-26 2011-11-30 重庆医药工业研究院有限责任公司 一种沙利度胺α晶型的工业化制备方法

Similar Documents

Publication Publication Date Title
JP2013528206A5 (enExample)
JP5099005B2 (ja) ヘテロ化合物
AU2019260159B2 (en) HPK1 inhibitors, preparation method and application thereof
CN103781764B (zh) 有害生物防除剂的制造法
ES2670093T3 (es) Antagonistas del receptor de P2X7 de tiazol u oxazol sustituidos
EP2511268A1 (en) Oxazine derivative
JP2014528948A5 (enExample)
JPH0256479A (ja) ピリドンカルボン酸系抗菌剤
CA2894016A1 (en) Modulators of the retinoid-related orphan receptor gamma (ror-gamma) for use in the treatment of autoimmune and inflammatory diseases
JP2016503391A5 (enExample)
BRPI0713684A2 (pt) compostos, composição farmaceuticamente aceitável e métodos de inibição da replicação de vìrus da hepatite c, de tratamento de célula e de tratamento ou prevenção da infecção do vìrus da hepatite c em maìfero carecido do mesmo
ES2658221T3 (es) Compuestos útiles en la síntesis de compuestos de benzamida
WO2013044811A1 (zh) 吉西他滨酰胺衍生物及其制备方法和用途
JP2012513381A5 (enExample)
PT1805170E (pt) Inibidores de mif
JP2020516616A5 (enExample)
AU2011263493B2 (en) Crystalline forms of thalidomide and processes for their preparation
WO2015064714A1 (ja) オートタキシン阻害活性を有する1-置換イミダゾピリミジノン誘導体
WO2013043520A1 (en) Triazolopyridyl compounds as aldosterone synthase inhibitors
WO2012063269A2 (en) Process for preparing iloperidone
WO2020143385A1 (zh) 芳基酰胺类抑制剂及其制备方法和应用
AU2012212622A1 (en) Methods for the preparation of bendamustine
JP2010524913A (ja) 炎症治療において有用なピラゾール
WO2012164582A1 (en) Preparation of 3-[2-[4-((6-fluoro-1, 2-benzisoxazol-3-yl)-l-piperidinyl)-6, 7, 8, 9-tetrahydro-9-hydroxy-2-methyl-4h-pyrido[ 1, 2-a]-pyrimidin-4-one (paliperidone) and paliperidone palmitate.
CA2879816C (en) Methanethione compounds having antiviral activity